GLP-1 medications have emerged as a possible pharmacological treatment for patients with non-alcoholic fatty liver disease.

 

Worldwide, non-alcoholic fatty liver disease (NAFLD) is now the most common liver disorder, with an estimated global prevalence of 32.4 percent.¹ NAFLD is associated with metabolic syndrome and ranges from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), inflammation and fibrosis, and cirrhosis. It is considered a systemic metabolic disorder because of its significant association with type 2 diabetes, obesity, hypertension, and dyslipidemia.¹

 

Despite the health burden of NAFLD, there are, to date, no approved pharmacological interventions that specifically target NAFLD. Lifestyle modifications and ≥7–10% weight loss are the sine qua non clinical recommendations to improve steatosis, necroinflammation, and fibrosis.^1,2,3 GLP-1 medications have now emerged as a possible treatment for NAFLD. Evidence robustly suggests they are efficacious for weight loss, glycemic control, and cardiometabolic risk, and there is mounting evidence to suggest they also demonstrate hepatoprotective properties.^4,5

 

Relevance of GLP-1s for Treating NAFLD
GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food intake. It stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety via central nervous system signaling. GLP-1 receptor agonists (GLP-1 RAs) could be beneficial in treating NAFLD in the following ways:

1. Weight loss and reduced caloric intake. GLP-1 RAs promote satiety, decrease appetite, and delay gastric emptying. Clinical trials report average weight loss of 1.5–6 kg with liraglutide, and up to 15 percent of body weight with semaglutide at higher doses.⁶ Weight reduction of ≥7–10 percent is strongly correlated with histologic improvement in NAFLD.⁷ The strongest evidence for GLP-1 RAs in NAFLD comes from their robust impact on weight. Trials consistently show weight loss across adults with obesity, type 2 diabetes, and NAFLD. For example, liraglutide achieved a mean weight loss of 8.4 kg over 1 year in non-diabetic adults with obesity.⁸ Semaglutide 2.4 mg/week achieved mean reductions of 9.6–17.4 percent of body weight in obesity trials, with 70.9 percent of participants achieving ≥10 percent weight loss.⁹ This degree of weight reduction exceeds the threshold associated with histological improvement in NASH.⁷
2. Improved glycemic control. By enhancing insulin sensitivity and reducing hepatic glucose output, GLP-1 RAs improve lipotoxicity and reduce hepatic triglyceride accumulation.¹⁰
3. Hepatic cytoprotection. Preclinical studies suggest GLP-1 RAs reduce oxidative stress, endoplasmic reticulum stress, and hepatocyte apoptosis, while promoting autophagy and fatty acid oxidation.^11,12

GLP-1s and Liver Enzymes
Reductions in liver enzymes have been consistently reported. For example, exenatide reduced ALT and AST in T2DM, with normalization in approximately 40 percent of patients.^13,14 Liraglutide lowered ALT in a dose-dependent manner — significant at 1.8 mg/day but not at lower doses¹⁵ — and dulaglutide improved liver enzymes in patients with type 2 diabetes and NAFLD.¹⁶ Semaglutide also reduced liver enzymes, producing dose-dependent reductions in ALT, maximal after 28–30 weeks, with improvements strongly linked to weight loss.^17,18

 

GLP-1s and Hepatic Steatosis
Several imaging and histology studies support reductions in liver fat. For example, exenatide decreased hepatic fat and improved the fatty liver index compared with other hypoglycemics.¹⁹ Liraglutide reduced liver fat by 44 percent on MR spectroscopy in women with polycystic ovary syndrome,²⁰ while in the LEAN trial,²¹ liraglutide improved steatosis. Semaglutide also significantly increased rates of NASH resolution without fibrosis progression compared with placebo.¹⁷

GLP-1s, Non-Alcoholic Steatohepatitis, and Fibrosis

In the LEAN trial, liraglutide led to NASH resolution in 38 percent of patients compared with nine percent in the placebo group at 48 weeks, and fibrosis progression was reduced (36 percent vs nine percent).²¹ In a 72-week trial, semaglutide achieved NASH resolution in 59 percent of participants compared with 17 percent in the placebo group. It should be noted that semaglutide did not significantly improve fibrosis stage, though fibrosis progression was reduced. Data from meta-analyses show that GLP-1s reduce ALT, hepatic fat content, and the risk of NASH, though it should be noted that antifibrotic efficacy is still an empirical uncertainty.^22,23

Implications for Clinical Practice

There is mounting evidence to support the use of GLP-1 RAs to treat NAFLD. GLP-1s have consistently demonstrated efficacy in helping patients with obesity and type 2 diabetes achieve clinically significant weight loss. The weight loss facilitated by GLP-1 medications like semaglutide can improve NASH histology, and liraglutide and semaglutide have each demonstrated efficacy in NASH resolution. The relationship with fibrosis warrants further investigation.

 

Health care providers should talk with their patients who have NAFLD about integrating a GLP-1 medication as part of a comprehensive treatment plan. These conversations should pair the benefits of pharmacological therapy with dietary and lifestyle changes and exercise.

 

For patients seeking a non-pharmacological pathway — or for those using GLP-1 therapy who need nutrition structure — Robard’s medically supervised programs (e.g., New Direction Advanced and Numetra) provide evidence-informed LCD/VLCD protocols paired with scientifically formulated meal replacements to help meet protein and micronutrient needs during weight reduction. In patients using GLP-1 medications, adjunctive nutrition support such as Biocare can provide essential nutrition and protein support and help with side-effect management commonly associated with GLP-1 therapy, while maintaining alignment with a structured, clinician-guided plan.

 

To learn more about how you can provide these programs and products to your patients, follow this link.

 

Source(s):

1 GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives

2 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non‐alcoholic fatty liver disease

3 Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

4 Mechanisms of action and therapeutic application of glucagon-like peptide-1

5 Cardiorenal impact of SGLT-2 inhibitors: A conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease

6  GLP-1 receptor agonists: An updated review of head-to-head clinical studies

7  EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease

8 A randomized, controlled trial of 3.0 mg of liraglutide in weight management

9 Once-weekly semaglutide in adults with overweight or obesity

10 Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

11 GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

12 Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway

13 Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

14 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

15 Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

16  Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: A post hoc analysis of the AWARD programme

17 A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

18 Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

19 Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes

20  Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial

21 Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study

22 Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

23 Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis

 

About the Author: Dr. Dawn M. Sweet has over 20 years of experience in the field of communication. Dr. Sweet has given several invited talks to and workshops for academic and private sector audiences on the role of nonverbal and verbal communication in achieving positive outcomes and mitigating bias. Her research has been published in several top ranked peer-review journals, and it has been featured on NPR’s River to River / All Things Considered, Buzzfeed, and Science Daily. Her research has also been used to inform expert testimony.

 

About Robard: Nationally recognized hospitals and physicians place their trust in Robard’s comprehensive medical weight management programs, evidence-based nutritional solutions, and specialized support designed to complement GLP-1 therapies, to effectively treat and manage patients with obesity. To learn more, visit us online at www.Robard.com, email us at info@robard.com, or call (800) 222-9201.